Protocol Specific Research Support (PSRS) supports innovative investigator-initiated pilot, phase 0, phase I, and phase l-ll trials led by AECC investigators. AECC leadership oversees these funds and provides support for research nurse or data managers for studies judged to be of high scientific priority by the PRMC. Eligibility for PSRS support requires that: (i) the study must be led by an AECC investigator, (ii) the study involves testing a candidate agent or device for diagnosis, prevention or treatment of cancer, (iii) the study can be completed within a reasonable period of time (usually <2 years) and (iv) the study not be fully funded by another mechanism. A process has been established for designating PSRS support for these pilot trials, which includes a screen by the CPDMU and PSRS Directors for PSRS eligibility, evaluation of scientific merit (as determined by the PRMC), and assigning priority relative to other AECC investigator initiated trials with a final recommendation by the Clinical Research Executive Committee. During the last funding period, trials supported by PSRS included a phase I first in human study of oncolytic virus Reolysin in patients with solid tumors, a phase I study of a combination of anti-CD19 and anti-CD22 immunotoxin (Combotox) in patients with hematological malignancies, and studies evaluating the clinical and biological effects of histone deacetylase and farnesyl transferase inhibitors in breast cancer. Other ongoing phase 0 or phase l-ll studies supported by PSRS include Combotox in combination with chemotherapy in leukemia, metronomic dosing of the PARP inhibitor veliparib and oral cyclophosphamide in breast cancer, and trials evaluating AKT inhibitors in breast cancer.
Protocol Specific Research Support (PSRS) supports innovative investigator-initiated pilot, phase 0, phase 1, and phase l-ll trials led by Albert Einstein Cancer Center (AECC) investigators. As an NCI-designated Cancer Center, AECC contributes to the national effort to reduce morbidity and mortality from cancer.
|Mirabello, Lisa; Clarke, Megan A; Nelson, Chase W et al. (2018) The Intersection of HPV Epidemiology, Genomics and Mechanistic Studies of HPV-Mediated Carcinogenesis. Viruses 10:|
|Gradissimo, Ana; Lam, Jessica; Attonito, John D et al. (2018) Methylation of High-Risk Human Papillomavirus Genomes Are Associated with Cervical Precancer in HIV-Positive Women. Cancer Epidemiol Biomarkers Prev 27:1407-1415|
|Drelon, Coralie; Belalcazar, Helen M; Secombe, Julie (2018) The Histone Demethylase KDM5 Is Essential for Larval Growth in Drosophila. Genetics 209:773-787|
|Hudgins, Adam D; Tazearslan, Cagdas; Tare, Archana et al. (2018) Age- and Tissue-Specific Expression of Senescence Biomarkers in Mice. Front Genet 9:59|
|Willis, Ian M; Moir, Robyn D; Hernandez, Nouria (2018) Metabolic programming a lean phenotype by deregulation of RNA polymerase III. Proc Natl Acad Sci U S A 115:12182-12187|
|Hayama, Ryo; Sparks, Samuel; Hecht, Lee M et al. (2018) Thermodynamic characterization of the multivalent interactions underlying rapid and selective translocation through the nuclear pore complex. J Biol Chem 293:4555-4563|
|Martynova, Elena; Bouchard, Maxime; Musil, Linda S et al. (2018) Identification of Novel Gata3 Distal Enhancers Active in Mouse Embryonic Lens. Dev Dyn 247:1186-1198|
|Huang, Kezhen; Mukherjee, Subhajit; DesMarais, Vera et al. (2018) Targeting the PXR-TLR4 signaling pathway to reduce intestinal inflammation in an experimental model of necrotizing enterocolitis. Pediatr Res 83:1031-1040|
|Bines, Jose; Tevaarwerk, Amye J (2018) Baby steps: Pregnancy outcomes after human epidermal growth factor receptor 2-targeted therapy. Cancer :|
|Mathew, Deepti; Wang, Yanhua; Van Arsdale, Anne et al. (2018) Expression of ?V-Tubulin in Secretory Cells of the Fallopian Tube Epithelium Marks Cellular Atypia. Int J Gynecol Cancer 28:363-370|
Showing the most recent 10 out of 1508 publications